Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

The trial included over 13,000 people across 30 countries and ran for more than 4.5 years, making it the largest and longest study on tirzepatide so far, the company said ...

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

GLP-1 weight loss medications like Ozempic and Wegovy could increase testosterone levels and help prevent erectile ...

Discover how tirzepatide benefits heart failure in obesity, and see why those with higher BMI may gain even more benefits.

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, ...